Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Payables (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Payables for 6 consecutive years, with $620528.0 as the latest value for Q3 2025.

  • Quarterly Payables fell 75.47% to $620528.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $620528.0 through Sep 2025, down 75.47% year-over-year, with the annual reading at $943019.0 for FY2024, 45.81% up from the prior year.
  • Payables for Q3 2025 was $620528.0 at Inhibikase Therapeutics, down from $2.7 million in the prior quarter.
  • The five-year high for Payables was $4.5 million in Q2 2022, with the low at $620528.0 in Q3 2025.
  • Average Payables over 5 years is $1.9 million, with a median of $1.7 million recorded in 2025.
  • The sharpest move saw Payables crashed 83.21% in 2023, then soared 347.53% in 2024.
  • Over 5 years, Payables stood at $1.3 million in 2021, then fell by 14.01% to $1.2 million in 2022, then plummeted by 43.82% to $646767.0 in 2023, then skyrocketed by 45.81% to $943019.0 in 2024, then plummeted by 34.2% to $620528.0 in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $620528.0, $2.7 million, and $1.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.